News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valeant Pharmaceuticals International (VRX) CEO Eyes Corporate "Fat" In Push For Big Leagues


3/20/2014 8:28:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

After Valeant Pharmaceuticals International Inc. (VRX) bought Bausch & Lomb Inc. for $8.7 billion last year, Chief Executive Officer Mike Pearson discovered the budget for the eyecare company’s communications team was 13 times the size of his own. Pearson set about cutting the budget and dismantled Bausch & Lomb’s structure of regional offices, costs he said are emblematic of how inefficient drug companies remain. Corporate excess is catnip to Pearson as he searches for acquisitions to meet his goal of making Valeant one of the world’s top five drugmakers by the end of 2016.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES